Skip to main content
Top
Published in: BMC Nephrology 1/2006

Open Access 01-12-2006 | Research article

Lessons for Medicare Part D in the hemodialysis community

Authors: Anisa I Nayeem, Glenn M Chertow

Published in: BMC Nephrology | Issue 1/2006

Login to get access

Abstract

Background

Medicare beneficiaries without prescription drug coverage consistently fill fewer prescriptions than beneficiaries with some form of drug coverage due to cost. ESRD patients, who are disproportionately poor and typically use multiple oral medications, would likely benefit substantially from any form of prescription drug coverage. Because most hemodialysis patients are Medicare-eligible, they as well as their providers would be expected to be well informed of changes in Medicare prescription drug coverage. By examining the level of understanding and use of the temporary Medicare Prescription Drug Discount Card Program in the hemodialysis population, we can gain a better understanding of the potential long-term utilization for Medicare Part D.

Methods

We surveyed English-speaking adult hemodialysis patients with Medicare coverage from two urban hemodialysis centers affiliated with the University of California San Francisco (UCSF) during July and August 2005 (n = 70). We also surveyed University- and community-based nephrologists and non-physician dialysis health care professionals over the same time frame (n = 70).

Results

Fifty-nine percent of patients received prescription drug coverage through Medi-Cal, 20% through another insurance program, and 21% had no prescription drug coverage. Forty percent of patients with no prescription drug coverage reported "sometimes" or "rarely" being able to obtain medications vs. 22% of patients with some form of drug coverage. None of the patients surveyed actually had a Medicare-approved prescription drug card, and of those who intended to apply, only 10% reported knowing how to do so. Only 11% health care professionals knew the eligibility requirements of the drug discount cards.

Conclusion

Despite a significant need, hemodialysis patients and providers were poorly educated about the Medicare Prescription Drug Discount Cards. This has broad implications for the dissemination of information about Medicare Part D.
Literature
2.
go back to reference Traynor K: Drug discount cards for Medicare beneficiaries to debut this year. Am J Health-Syst Pharm. 2004, 61: 224-7.PubMed Traynor K: Drug discount cards for Medicare beneficiaries to debut this year. Am J Health-Syst Pharm. 2004, 61: 224-7.PubMed
5.
go back to reference United States Renal Data System. Annual Data Report. 2005 United States Renal Data System. Annual Data Report. 2005
6.
go back to reference Stubenrauch JM: Pick a card – any card? Helping patients understand the new Medicare approved drug discount cards. Am J Nurs. 2004, 104: 24-6.CrossRefPubMed Stubenrauch JM: Pick a card – any card? Helping patients understand the new Medicare approved drug discount cards. Am J Nurs. 2004, 104: 24-6.CrossRefPubMed
8.
go back to reference The Centers for Medicare & Medicaid Services: Medicare Fact Sheet: Medicare Prescription Drug Discount Card and Transitional Assistance Program. 2004, Accessed 9/20/05, [http://www.cms.hhs.gov] The Centers for Medicare & Medicaid Services: Medicare Fact Sheet: Medicare Prescription Drug Discount Card and Transitional Assistance Program. 2004, Accessed 9/20/05, [http://​www.​cms.​hhs.​gov]
Metadata
Title
Lessons for Medicare Part D in the hemodialysis community
Authors
Anisa I Nayeem
Glenn M Chertow
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2006
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-7-11

Other articles of this Issue 1/2006

BMC Nephrology 1/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.